Atreca Moves Toward Final Liquidation as CVRs Hinge on Immunome Agreement

Atreca, the biotechnology firm, is in the final phase of its wind-down and formal dissolution. Shareholders had already endorsed this course of action in May 2024, and the company’s operating core effectively ceased long before. For former investors, the focus now centers on whether any remaining rights can be monetized.

• Liquidation dividend of $0.05 per share paid in late December 2024.
• Nasdaq trading ended in mid-2024 following the delisting.
• The sale of 28 antibody programs to Immunome has been completed.

The core of the remaining claims revolves around Contingent Value Rights (CVRs). These non-transferable rights were issued to shareholders as part of the dissolution plan and offer Read more...